MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome

Wu, Shanshan; Sun, Haixia; Sun, Bin

doi:10.1186/s40001-020-00403-8

Cited by 17 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A consistent finding was more recently reported also in human carotid artery stenosis [ 49 ]. Moreover, downregulation of miR-145 was also proposed as a marker of coronary event involving plaque rupture [ 50 ], reinforcing the concept that a balanced expression of this miR could be actively implicated in vascular health and stability.…”

Section: Discussionmentioning

confidence: 99%

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan

et al. 2021

View full text Add to dashboard Cite

miR profile could be associated to CV risk, and also to prognosis/outcome in response to therapeutic approach. We aimed to evaluate if anti-hypertensive drugs enalapril, losartan or olmesartan have effects on monocyte miR profile in essential hypertensives without target organ involvement. For this purpose, 82 hypertensives and 49 controls were included; we evaluated SBP/DBP, lipid profile, glucose, CRP, fibrinogen, arterial stiffness indices (PWV; AIx), and cIMT at baseline (T0) and after 24 weeks of treatment (T1). Subjects with LDL-C ≥ 160 mg/dL, TG ≥ 200 mg/dL, BMI ≥ 30, and other additional CV risk factors were excluded. Patients who were prescribed to receive once-a-day enalapril 20 mg, losartan 100 mg or olmesartan 20 mg were eligible for the study. At T1, we found a significant improvement of SBP (−18.5%), DBP (−18%), HDL-C and LDL-C (+3% and −5.42%), glucose (−2.15%), BMI (−3.23%), fibrinogen (−11%), CRP (−17.5%,), AIx (−49.1%) PWV (−32.2%), and monocyte miR expression (miR-221: −28.4%; miR-222: −36%; miR-145: +41.7%) with respect to baseline. miR profile was compared to control subjects at baseline and at T1. We found some little difference in the behaviour of the three treatments on some variables: olmesartan was the most effective in reducing fibrinogen, DBP, CRP, and AIx (−13.1%, −19.3%, −21.4%, and −56.8%, respectively). Enalapril was the drug more significantly increasing the expression of miR-145. In conclusion, enalapril, losartan and olmesartan are effective in improving mechanical and humoral factors associated to AS and atherogenesis. These drugs appear to be able to modify miRs 221/222 and miR-145 expression in drug-naïve hypertensives, making it closer to that of control subjects; additionally, this provides a good blood pressure compensation, contributing to slow the progression of vascular damage.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For example, miR-587 showed a close association with the severity of ACS patients and was considered to be a potential biomarker for the diagnosis and prognosis of ACS [ 29 ]. miR-145 was disclosed to participate in the dysfunction of endothelial cells and differentiate ACS patients from healthy controls [ 30 ]. In this study, miR-3646 was found to be upregulated in ACS patients and discriminate ACS patients from healthy volunteers and non-ACS patients with high sensitivity and specificity.…”

Section: Discussionmentioning

confidence: 99%

microRNA-3646 serves as a diagnostic marker and mediates the inflammatory response induced by acute coronary syndrome

Leng

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Acute coronary syndrome (ACS) is one of the main syndromes of coronary artery disease with high mortality. The identification of biomarkers associated with disease occurrence and progression could improve early detection and risk prediction. This study was aimed to reveal the clinical significance and function of miR-3646 in ACS.The expression of miR-3646 was evaluated in ACS patients, healthy volunteers, and non-ACS patients and estimated the clinical significance of miR-3646. The ACS modeling rats were also established in this study to explore the potential mechanism underlying the function of miR-3646. miR-3646 was upregulated in ACS patients compared with healthy volunteers and non-ACS patients. The expression of miR-3646 was positively correlated with the severity and progression of ACS patients and could discriminate ACS patients from healthy volunteers and non-ACS patients. The knockdown of miR-3646 could reverse the inflammatory response induced by ACS.miR-3646 serves as a diagnostic biomarker for ACS. The knockdown of miR-3646 could alleviate ACS by reversing inflammatory response. These results provide a potential therapeutic target of ACS.

show abstract

“…Another study by Wu and colleagues [ 33 ] revealed the function of miR-145 in regulating vascular endothelial cells and inflammation response by targeting the same FOXO1 gene. The miR-145 expression was found to be low in patients with ACS and negatively correlated with endothelial injury biomarkers and pro-inflammatory cytokines.…”

Section: Current Outlooks For Mirnas In Ischemic Heart Diseasementioning

confidence: 99%

miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Kong

Lai

Lim

et al. 2022

IJMS

View full text Add to dashboard Cite

Ischemic heart disease (IHD) constitutes the leading global cause of mortality and morbidity. Although significant progress has been achieved in the diagnosis, treatment, and prognosis of IHD, more robust diagnostic biomarkers and therapeutic interventions are still needed to circumvent the increasing incidence of IHD. MicroRNAs (miRNAs) are critical regulators of cardiovascular function and are involved in various facets of cardiovascular biology. While the knowledge of the role of miRNAs in IHD as diagnostic biomarkers has improved, research emphasis on how miRNAs can be effectively used for diagnosis and prognosis of IHD is crucial. This review provides an overview of the biology, therapeutic and diagnostic potential, as well as the caveats of using miRNAs in IHD based on existing research.

show abstract

MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome

Cited by 17 publications

References 45 publications

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan

microRNA-3646 serves as a diagnostic marker and mediates the inflammatory response induced by acute coronary syndrome

miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Contact Info

Product

Resources

About